Evidence map›Paper›PMID 36443316›Full record

ArticleScientific reports2022

Serum circulating sirtuin 6 as a novel predictor of mortality after acute ischemic stroke.

Luca Liberale, Stefano Ministrini, Markus Arnold, Yustina M Puspitasari, Thomas Pokorny, Georgia Beer, Natalie Scherrer, Juliane Schweizer, Mirjam Christ-Crain, Fabrizio Montecucco and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Serum SIRT6 Levels Are Associated with Frailty in Older Adults.The journal of nutrition, health & aging · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Luca Liberale *First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, Genoa, Italy.
Stefano Ministrini *Center for Molecular Cardiology, University of Zurich, Schlieren, Switzerland.
Markus ArnoldDepartment of Neurology, University Hospital and University of Zurich, Zurich, Switzerland.
Yustina M PuspitasariCenter for Molecular Cardiology, University of Zurich, Schlieren, Switzerland.
Thomas PokornyDepartment of Neurology, University Hospital and University of Zurich, Zurich, Switzerland.
Georgia BeerCenter for Molecular Cardiology, University of Zurich, Schlieren, Switzerland.
Natalie ScherrerDepartment of Neurology, University Hospital and University of Zurich, Zurich, Switzerland.
Juliane SchweizerDepartment of Neurology, University Hospital and University of Zurich, Zurich, Switzerland.
Mirjam Christ-CrainDepartment of Endocrinology, University Hospital of Basel, Basel, Switzerland.
Fabrizio MontecuccoFirst Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, Genoa, Italy.
Giovanni G CamiciCenter for Molecular Cardiology, University of Zurich, Schlieren, Switzerland.
Mira Katan KahlesDepartment of Neurology, University Hospital and University of Zurich, Zurich, Switzerland. mira.katan@usb.ch.
University Hospital of Zurich · CHUniversity of Zurich · CHUniversity of Genoa · ITUniversity Hospital of Basel · CHUniversity of Perugia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In a murine model of acute ischemic stroke, SIRT6 knockdown resulted in larger cerebral infarct size, worse neurological outcome, and higher mortality, indicating a possible neuro-protective role of SIRT6. In this study, we aimed at evaluating the prognostic value of serum SIRT6 levels in patients with acute ischemic stroke (AIS). Serum levels of SIRT6, collected within 72 h from symptom-onset, were measured in 317 consecutively enrolled AIS patients from the COSMOS cohort. The primary endpoint of this analysis was 90-day mortality. The independent prognostic value of SIRT6 was assessed with multivariate logistic and Cox proportional regression models. 35 patients (11%) deceased within 90-day follow-up. After adjustment for established risk factors (age, NIHSS, heart failure, atrial fibrillation, and C reactive protein), SIRT6 levels were negatively associated with mortality. The optimal cut-off for survival was 634 pg/mL. Patients with SIRT6 levels below this threshold had a higher risk of death in multivariable Cox regression. In this pilot study, SIRT6 levels were significantly associated with 90-day mortality after AIS; these results build on previous molecular and causal observations made in animal models. Should this association be confirmed, SIRT6 could be a potential prognostic predictor and therapeutic target in AIS.

Indexed as

Atrial FibrillationIschemic StrokeSirtuinsAnimalsCerebral InfarctionGlycosyltransferasesMicePilot ProjectsGlycosyltransferasesSIRT6 protein, humanSirt6 protein, mouseSirtuins

Identifiers

PMID36443316
PMCPMC9705558
OpenAlexW4310086895

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.